Purchase this article with an account.
J. M. Rosenthal, J. Hsu, M. J. Spirn, S. J. Garg; Systemic Fluoroquinolone Antibiotic Use in Postoperative Endophthalmitis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3559.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To examine the effect of systemic moxifloxacin in the treatment of postoperative endophthalmitis.
We performed a retrospective review of patients with acute postoperative endophthalmitis presenting to the Retina Service of Wills Eye Institute from February 2005 to August 2007. Patients included developed endophthalmitis within 6 weeks of cataract surgery or intraocular lens exchange and had visual acuities (VA) of hand motions or better. All underwent a vitreous or aqueous biopsy with injection of intravitreal antibiotics and received topical antibiotic drops. Patients were divided into those who either received systemic moxifloxacin (MOXI group) or did not (NO MOXI group).
67 patients were included in the study, 35 of whom were given systemic moxifloxacin. The initial mean logMAR VA were 2.04 and 1.93 in the MOXI and NO MOXI groups, respectively. Length of follow-up ranged from 1 day to 36 months. At one week, the mean logMAR VA was 1.81 in the MOXI group and 1.92 in the NO MOXI group. At 6 weeks, the mean logMAR VA was 1.43 (approx. 20/550) and 1.61 (approx. 20/800) in the MOXI and NO MOXI groups, respectively. At six months, the mean logMAR VA was 1.13 (approx. 20/250) and 1.30 (approx. 20/400) in the MOXI and NO MOXI groups, respectively.
This PDF is available to Subscribers Only